Distal and local mucosal immunization with a BoHV-4-based vector delivering CpHV-1 gD confers protection against intravaginal CpHV-1 challenge in goats
Clinical Scorecard: Mucosal Immunization via a BoHV-4 Vector Expressing CpHV-1 gD Provides Protection Against Intravaginal CpHV-1 Infection in Goats
At a Glance
Category Detail
Condition Caprine herpesvirus 1 (CpHV-1) infection Key Mechanisms Mucosal vaccination using a BoHV-4 vector expressing CpHV-1 glycoprotein D induces protective immunity. Target Population Goats Care Setting Veterinary clinical research
Key Highlights
BoHV-4 vector vaccination provides complete protection against CpHV-1 infection. Both intravaginal and intranasal routes induce systemic antibody responses. Intravaginal immunization shows superior control of genital virus excretion. Guideline-Based Recommendations
Diagnosis
Evaluate CpHV-1 infection through clinical signs such as vulvovaginitis and abortion. Management
Utilize BoHV-4-based vectors for mucosal vaccination against CpHV-1. Monitoring & Follow-up
Assess viral shedding and immune response post-vaccination. Risks
Monitor for potential adverse effects related to vaccination. Patient & Prescribing Data
Goats at risk of CpHV-1 infection.
Mucosal vaccination strategies are effective in inducing protective immunity.
Clinical Best Practices
Implement mucosal vaccination to enhance local immune responses. Consider both local and distal routes for vaccination to optimize protection. Related Resources & Content
